Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 4/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | BCR | P11274 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.36 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.36 |
| ▸ | CCNK | O75909 | 1/20 | 0.36 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30664223 | 1.00 | MAOA (0.44) | MAOADYRK1AL3MBTL1KDM5BALK | |
| SCHEMBL30664178 | 0.84 | CREBBP (0.43) | MAOAKDM5BALKCREBBPGRIN1 | |
| SCHEMBL20123064 | 0.84 | CREBBP (0.43) | MAOAKDM5BALKCREBBPGRIN1 | |
| SCHEMBL20122959 | 0.81 | MAOA (0.44) | MAOADYRK1ACCNKCDK12MAPK1 | |
| SCHEMBL30664329 | 0.81 | MAOA (0.44) | MAOADYRK1ACCNKCDK12MAPK1 | |
| SCHEMBL29756420 | 0.80 | L3MBTL1 (0.42) | DYRK1AL3MBTL1KDM5BALKCREBBP | |
| SCHEMBL20122987 | 0.80 | L3MBTL1 (0.42) | DYRK1AL3MBTL1KDM5BALKCREBBP | |
| SCHEMBL20122768 | 0.79 | AURKA (0.43) | MAOADYRK1AMAPK1CYP3A4 | |
| SCHEMBL30664333 | 0.79 | AURKA (0.43) | MAOADYRK1AMAPK1CYP3A4 | |
| SCHEMBL20123074 | 0.77 | L3MBTL1 (0.39) | DYRK1AL3MBTL1KDM5BALKCREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827633-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | SANOFI (FR) | 2023-11-28 | — | — | US | disclosed |
| US-11827633-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | SANOFI (FR) | 2023-11-28 | — | — | US | disclosed |
| US-11130755-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | SANOFI (FR) | 2021-09-28 | — | — | US | disclosed |
| EP-3792262-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | SANOFI (FR) | 2021-03-17 | — | — | EP | disclosed |
| EP-3535263-B1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | SANOFI SA (FR) | 2020-09-30 | — | — | EP | disclosed |
| EP-3318563-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | SANOFI (FR) | 2018-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827633-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | COL2A1, IDO1, COL1A1 | MAOA 245/4885DYRK1A 493/4885L3MBTL1 3291/4885 |
| US-11130755-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | COL2A1, IDO1, COL1A1 | MAOA 245/4885DYRK1A 493/4885L3MBTL1 3291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.